Lifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults.
body mass index
insulin resistance
lifetime marijuana use
体重指数
终生吸食大麻
胰岛素抵抗
Journal
Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
28
01
2019
revised:
13
05
2019
accepted:
29
05
2019
pubmed:
4
6
2019
medline:
9
6
2020
entrez:
2
6
2019
Statut:
ppublish
Résumé
Obese individuals are more likely to show insulin resistance (IR). However, limited population studies on marijuana use with markers of IR have yielded mixed results. The aim of this study was to examine the association of marijuana use with IR in US adults with different body mass index (BMI) status. Data from the 2009 to 2016 National Health and Nutrition Examination Survey (NHANES) were abstracted. Minimal lifetime marijuana use was estimated using the duration of regular exposure and frequency of use. The association of marijuana use with both fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR) was determined in lean, overweight, and obese individuals separately using generalized linear models. Interview weight years of data were used to account for the unequal probability of sampling and non-response. Of all 129 509 adults aged 18 to 59 years, 50.3% were women. In current obese marijuana consumers, mean FINS in those with less than four uses per month was 52% (95% confidence interval [CI] 19%-71%) lower than in never users. In former obese consumers with eight or more uses per month and who stopped marijuana use <12 months ago, mean FINS was 47% (95% CI 18%-66%) lower than in never users. Mean FINS in those who quit marijuana 12 to 119 and 120 months and more prior the survey was 36% (95% CI 7%-57%) and 36% (95% CI 10%-54%) lower, respectively. Marijuana use is associated with lower FINS and HOMA-IR in obese but not non-obese adults, even at low frequency of less than four uses per month. Former marijuana consumers with high lifetime use had significantly lower FINS levels that persisted, independent of the duration of time since last use. 背景: 肥胖者更易出现胰岛素抵抗(insulin resistance, IR)。然而, 关于大麻使用与IR标记物的有限人群研究产生了不同的结果。本研究的目的是在不同体重指数(BMI)的美国成年人当中评估吸食大麻与IR之间的关系。 方法: 提取2009-2016年全国健康与营养调查研究(NHANES)的数据。使用定期吸食的持续时间以及吸食的频率来评估最小量的终身吸食大麻持续时间。使用广义线性模型分别在消瘦、超重以及肥胖的个体当中评估吸食大麻与空腹胰岛素(both fasting insulin, FINS)以及使用稳态模型评估的胰岛素抵抗(HOMA-IR)之间的关系。使用访谈权重年数据来解释抽样与无应答的概率不均衡。 结果: 共有129 509例18-59岁的成人, 其中50.3%为女性。在当前吸食大麻的肥胖个体中, 每月吸食次数少于4次的个体平均FINS要比从未吸食者低52%(95%置信区间[CI]:19%-71%)。在每月吸食8次或以上且在<12个月前停用大麻的既往肥胖患者中, 平均FINS要比从未吸食者低47%(95% CI:18%-66%)。在调查之前12~119个月与≥120个月就停止吸食大麻的个体平均FINS比从未吸食者分别低36%(95% CI:7%-57%)与36%(95% CI:10%-54%)。 结论: 与非肥胖的成年人相比, 肥胖的成年人吸食大麻后可导致FINS以及HOMA-IR降低, 即使他们每月吸食大麻的频率少于4次时也是如此。过去曾长期大量吸食大麻的个体的FINS水平显著降低, 并且与最后一次吸食后停吸的时间无关。.
Sections du résumé
BACKGROUND
BACKGROUND
Obese individuals are more likely to show insulin resistance (IR). However, limited population studies on marijuana use with markers of IR have yielded mixed results. The aim of this study was to examine the association of marijuana use with IR in US adults with different body mass index (BMI) status.
METHODS
METHODS
Data from the 2009 to 2016 National Health and Nutrition Examination Survey (NHANES) were abstracted. Minimal lifetime marijuana use was estimated using the duration of regular exposure and frequency of use. The association of marijuana use with both fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR) was determined in lean, overweight, and obese individuals separately using generalized linear models. Interview weight years of data were used to account for the unequal probability of sampling and non-response.
RESULTS
RESULTS
Of all 129 509 adults aged 18 to 59 years, 50.3% were women. In current obese marijuana consumers, mean FINS in those with less than four uses per month was 52% (95% confidence interval [CI] 19%-71%) lower than in never users. In former obese consumers with eight or more uses per month and who stopped marijuana use <12 months ago, mean FINS was 47% (95% CI 18%-66%) lower than in never users. Mean FINS in those who quit marijuana 12 to 119 and 120 months and more prior the survey was 36% (95% CI 7%-57%) and 36% (95% CI 10%-54%) lower, respectively.
CONCLUSIONS
CONCLUSIONS
Marijuana use is associated with lower FINS and HOMA-IR in obese but not non-obese adults, even at low frequency of less than four uses per month. Former marijuana consumers with high lifetime use had significantly lower FINS levels that persisted, independent of the duration of time since last use.
背景: 肥胖者更易出现胰岛素抵抗(insulin resistance, IR)。然而, 关于大麻使用与IR标记物的有限人群研究产生了不同的结果。本研究的目的是在不同体重指数(BMI)的美国成年人当中评估吸食大麻与IR之间的关系。 方法: 提取2009-2016年全国健康与营养调查研究(NHANES)的数据。使用定期吸食的持续时间以及吸食的频率来评估最小量的终身吸食大麻持续时间。使用广义线性模型分别在消瘦、超重以及肥胖的个体当中评估吸食大麻与空腹胰岛素(both fasting insulin, FINS)以及使用稳态模型评估的胰岛素抵抗(HOMA-IR)之间的关系。使用访谈权重年数据来解释抽样与无应答的概率不均衡。 结果: 共有129 509例18-59岁的成人, 其中50.3%为女性。在当前吸食大麻的肥胖个体中, 每月吸食次数少于4次的个体平均FINS要比从未吸食者低52%(95%置信区间[CI]:19%-71%)。在每月吸食8次或以上且在<12个月前停用大麻的既往肥胖患者中, 平均FINS要比从未吸食者低47%(95% CI:18%-66%)。在调查之前12~119个月与≥120个月就停止吸食大麻的个体平均FINS比从未吸食者分别低36%(95% CI:7%-57%)与36%(95% CI:10%-54%)。 结论: 与非肥胖的成年人相比, 肥胖的成年人吸食大麻后可导致FINS以及HOMA-IR降低, 即使他们每月吸食大麻的频率少于4次时也是如此。过去曾长期大量吸食大麻的个体的FINS水平显著降低, 并且与最后一次吸食后停吸的时间无关。.
Autres résumés
Type: Publisher
(chi)
背景: 肥胖者更易出现胰岛素抵抗(insulin resistance, IR)。然而, 关于大麻使用与IR标记物的有限人群研究产生了不同的结果。本研究的目的是在不同体重指数(BMI)的美国成年人当中评估吸食大麻与IR之间的关系。 方法: 提取2009-2016年全国健康与营养调查研究(NHANES)的数据。使用定期吸食的持续时间以及吸食的频率来评估最小量的终身吸食大麻持续时间。使用广义线性模型分别在消瘦、超重以及肥胖的个体当中评估吸食大麻与空腹胰岛素(both fasting insulin, FINS)以及使用稳态模型评估的胰岛素抵抗(HOMA-IR)之间的关系。使用访谈权重年数据来解释抽样与无应答的概率不均衡。 结果: 共有129 509例18-59岁的成人, 其中50.3%为女性。在当前吸食大麻的肥胖个体中, 每月吸食次数少于4次的个体平均FINS要比从未吸食者低52%(95%置信区间[CI]:19%-71%)。在每月吸食8次或以上且在<12个月前停用大麻的既往肥胖患者中, 平均FINS要比从未吸食者低47%(95% CI:18%-66%)。在调查之前12~119个月与≥120个月就停止吸食大麻的个体平均FINS比从未吸食者分别低36%(95% CI:7%-57%)与36%(95% CI:10%-54%)。 结论: 与非肥胖的成年人相比, 肥胖的成年人吸食大麻后可导致FINS以及HOMA-IR降低, 即使他们每月吸食大麻的频率少于4次时也是如此。过去曾长期大量吸食大麻的个体的FINS水平显著降低, 并且与最后一次吸食后停吸的时间无关。.
Identifiants
pubmed: 31152633
doi: 10.1111/1753-0407.12958
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-47Subventions
Organisme : CIHR
ID : 331786
Pays : Canada
Informations de copyright
© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Johnston LD, O'Malley PM, Bachman JG. Monitoring the Future National Survey Results on Drug Use, 1975-2002. National Institute on Drug Abuse: Bethesda, MD; 2003.
Canadian Centre on Substance Use and Addiction. Cannabis. https://www.cpha.ca/sites/default/files/uploads/resources/cannabis/ccsa-canadian-drug-summary-cannabis-2017-en.pdf. Published August 2017. Accessed December 23, 2018.
United Nations Office on Drugs and Crime (UNODC). World drug report 2018. https://www.unodc.org/wdr2018/. Published 2018. Accessed December 22, 2018.
Han B, Compton WM, Blanco C, Jones CM. Trends in and correlates of medical marijuana use among adults in the United States. Drug Alcohol Depend. 2018;186:120-129.
Rotermann M, Macdonald R. Analysis of trends in the prevalence of cannabis use in Canada, 1985 to 2015. Health Rep. 2018;29:10-20.
Rezkella S, Kloner RA. Cardiovascular effects of marijuana. Trends Cardiovasc Med. 2018 (in press). https://doi.org/10.1016/j.tcm.2018.11.004.
Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med. 2007;167:221-228.
Lovell ME, Bruno R, Johnston J, et al. Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. Addict Behav. 2018;79:178-188.
Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci. 2007;64:219-229.
Motaghedi R, McGraw TE. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity. 2008;16:1727-1734.
Bermúdez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB(1) receptors induces glucose intolerance in rats. Eur J Pharmacol. 2006;531:282-284.
Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27-37.
Muniyappa R, Sable S, Ouwerkerk R, et al. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013;36:2415-2422.
Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. Am J Med. 2013;126:583-589.
Ngueta G, Bélanger RE, Laouan-Sidi EA, Lucas M. Cannabis use in relation to obesity and insulin resistance in the Inuit population. Obesity. 2015;23:290-295.
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133-2223.
Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013;7:14-24.
Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21:1443-1455.
US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey. Hyattsville, MD: US Department of Health and Human Services, CDC. http://www.cdc.gov/nchs/nhanes.htm. 2016. Accessed January 8, 2019.
Thomas GN, Critchley JA, Tomlinson B, Anderson PJ, Lee ZS, Chan JC. Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism. 2000;49:1523-1528.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25:1177-1184.
US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). Blood and Urine Collection. Hyattsville, MD: US Department of Health and Human Services, CDC. https://www.cdc.gov/nchs/data/nhanes/nhanes_09_10/labcomp_f.pdf. December 2010. Accessed January 8, 2019.
US Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey: Serum, Plasma and Urine Specimens. Hyattsville, MD: US Department of Health and Human Services, CDC. https://www.cdc.gov/nchs/nhanes/biospecimens/serum_plasma_urine.htm. December 2014. Accessed January 8, 2019.
Textor J, Liskiewicz M. Adjustment criteria in causal diagrams: an algorithmic perspective. Paper presented at: 27th Conference on Uncertainty in Artificial Intelligence (UAI 2011); July 14-17, 2011; Barcelona, Spain. http://arxiv.org/ftp/arxiv/papers/1202/1202.3764.pdf. Accessed January 8, 2019.
Textor J, Hardt J, Knüppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology. 2011;5:745.
US Census Bureau. How the Census Bureau Bureau measures poverty. https://www.census.gov/topics/income-poverty/poverty/guidance/poverty-measures.html. 2019. Accessed 30 May 2019.
Kandula NR, Diez-Roux AV, Chan C, et al. Association of acculturation levels and prevalence of diabetes in the multi-ethnic study of atherosclerosis (MESA). Diabetes Care. 2008;31:1621-1628.
González-Mariscal I, Krzysik-Walker SM, Kim W, Rouse M, Egan JM. Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice. Mol Cell Endocrinol. 2016;423:1-10.
Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors. Regul Pept. 2008;145:49-53.
Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest. 1998;102:869-873.
Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm. 2013;2013:139239.
Ota T. Obesity-induced inflammation and insulin resistance. Front Endocrinol. 2014;5:204.
Blüher M. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? Clin Sci. 2016;130:1603-1614.
Levendal RA, Schumann D, Donath M, Frost CL. Cannabis exposure associated with weight reduction and β-cell protection in an obese rat model. Phytomedicine. 2012;19:575-582.
Chan CB, De Leo D, Joseph JW, et al. Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001;50:1302-1310.
Dalgaard LT, Pedersen O. Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes. Diabetologia. 2001;44:946-965.
Iwasaki Y, Iwasaki H, Yatoh S, et al. Nuclear SREBP-1a causes loss of pancreatic beta-cells and impaired insulin secretion. Biochem Biophys Res Commun. 2009;378:545-550.
Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001;105:745-755.
Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840-846.
Katsiki N, Tziomalos K, Mikhailidis DP. Alcohol and the cardiovascular system: a double-edged sword. Curr Pharm Des. 2014;20:6276-6288.
Villegas R, Salim A, O'Halloran D, Perry IJ. Alcohol intake and insulin resistance. A cross-sectional study. Nutr Metab Cardiovasc Dis. 2004;14:233-240.
Babson KA, Boden MT, Bonn-Miller MO. The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav. 2013;38:2707-2713.
Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature. 2016;539:369-377.
Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770-1804.
Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149-156.